Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Pfizer-Valneva Lyme vaccine shows more than 70% efficacy but misses key goal

March 23 (Reuters) - Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a ...

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...